Drug Profile

hNPC 01

Alternative Names: hNPC-01

Latest Information Update: 12 Mar 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Hopstem Biotechnology
Class Induced pluripotent stem cell therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Stroke
Research Cerebral palsy; Traumatic brain injuries

Most Recent Events

09 Nov 2023 Phase-I clinical trials in Stroke in China (Intracerebral) (NCT06299033)
02 Nov 2021 Hopstem Biotechnology plans phase I trials for Traumatic brain injury and Cerebral palsy in first second half of 2022 (Hopstem Biotechnology pipeline, November 2021)
31 Oct 2021 Hopstem Biotechnology plans to file IND application for Stroke in USA and China

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com